Journal Article

DZNE-2026-00255

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Longitudinal monitoring of tau aggregation in progressive supranuclear palsy with [18F]PI-2620 PET.

Gnörich, J. (First author)DZNE* ; Kusche-Palenga, J. ; Palleis, C.DZNE* ; Neubauer, A.DZNE* ; Frontzkowski, L. ; Jäck, A.DZNE* ; Kling, A. ; Bauer, T. ; Eyob, H. ; Probst, K. ; Roemer-Cassiano, S. N. ; Bernhardt, A. M.DZNE* ; Katzdobler, S.DZNE* ; Marth, L.DZNE* ; Zaganjori, M. ; Hopfner, F.Extern* ; Zwergal, A. ; Häckert, J. ; Rullmann, M. ; Sabri, O.Extern* ; Barthel, H. ; Stöcklein, S.Extern* ; Werner, R. A. ; Simons, M.DZNE* ; Levin, J.DZNE* ; Herms, J.DZNE* ; Franzmeier, N. ; Höglinger, G. U.DZNE* ; Brendel, M. (Last author)DZNE* ; Tauopathies, G. I. I. f. (Collaboration Author)

2026
Wiley Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/alz.71195

Abstract: Progressive supranuclear palsy (PSP), a 4-repeat tauopathy, can be visualized using [18F]PI-2620 tau positron emission tomography (PET). However, the value of sequential [18F]PI-2620 imaging for tracking tau accumulation during the disease course has not yet been investigated.Twenty-three PSP patients underwent two [18F]PI-2620 PET scans (interval: 21.4 ± 4.3 months) and were compared to cross-sectional data from 25 healthy controls. Regional volume of distribution ratio values were analyzed for longitudinal tau changes, clinical correlations, and network-based propagation. Post mortem analyses examined neuronal density and AT8 tau pathology.Subcortical tau PET signals increased, strongest in the globus pallidus internus (P < 0.0001). Patients with low baseline tau showed the largest increases. Despite clinical worsening (Progressive Supranuclear Palsy Rating Scale +48%), tau PET change did not correlate with symptom progression. Tau accumulation followed functional connectivity (R = 0.34, P < 0.0001). Post mortem data linked elevated tau PET to higher AT8 burden despite neuronal loss.[18F]PI-2620 PET enables monitoring of tau progression in PSP, indicating network-based tau propagation with saturation in advanced stages.

Keyword(s): Humans (MeSH) ; Supranuclear Palsy, Progressive: diagnostic imaging (MeSH) ; Supranuclear Palsy, Progressive: metabolism (MeSH) ; Supranuclear Palsy, Progressive: pathology (MeSH) ; Positron-Emission Tomography (MeSH) ; tau Proteins: metabolism (MeSH) ; Male (MeSH) ; Female (MeSH) ; Aged (MeSH) ; Longitudinal Studies (MeSH) ; Middle Aged (MeSH) ; Disease Progression (MeSH) ; Brain: diagnostic imaging (MeSH) ; Brain: metabolism (MeSH) ; Brain: pathology (MeSH) ; Cross-Sectional Studies (MeSH) ; Fluorine Radioisotopes (MeSH) ; Pyridines (MeSH) ; 4‐repeat tauopathies ; disease monitoring ; progressive supranuclear palsy ; tau positron emission tomography ; tau spreading ; tau Proteins ; Fluorine Radioisotopes ; PI-2620 ; Pyridines

---

Contributing Institute(s):

1. Molecular Neurodegeneration (AG Haass)
2. Clinical Research (Munich) (Clinical Research (Munich))
3. Translational Brain Research (AG Herms)
4. Molecular Neurobiology (AG Simons)
5. Clinical Neurodegeneration (AG Levin)

Research Program(s):

1. 352 - Disease Mechanisms (POF4-352) (POF4-352)
2. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
3. 351 - Brain Function (POF4-351) (POF4-351)

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---